


PRODUCT INFORMATION



Levobunolol (hydrochloride)

Item No. 21005

CAS Registry No.: 27912-14-7
Formal Name: 5-[(2S)-3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-3,4-dihydro-1(2H)-naphthalenone, monohydrochloride
Synonyms: AG-901, (-)-Bunolol, W-7000A
MF: C₁₇H₂₅NO₃ • HCl
FW: 327.9
Purity: ≥98%
UV/Vis.: λ_{max}: 222, 254, 312 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Levobunolol (hydrochloride) is supplied as a crystalline solid. A stock solution may be made by dissolving the levobunolol (hydrochloride) in the solvent of choice, which should be purged with an inert gas. Levobunolol (hydrochloride) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of levobunolol (hydrochloride) in these solvents is approximately 11, 16, and 14 mg/ml, respectively.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of levobunolol (hydrochloride) can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of levobunolol (hydrochloride) in PBS, pH 7.2, is approximately 5 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

Levobunolol (hydrochloride) is a β-adrenergic antagonist that acts as a vasodilator and increases ocular circulation when applied in solution to the eye.¹ Topical formulations containing levobunolol are used to manage glaucoma.²

References

1. Tierney, D.W. Betaxolol and levobunolol: New beta-blocking antiglaucoma agents. *J. Am. Optom. Assoc.* **58**(9), 722-727 (1987).
2. Morsman, C.D., Boscman, M.E., Lusky, M., *et al.* The effect of topical beta-adrenoceptor blocking agents on pulsatile ocular blood flow. *Eye (Lond)* **9**(Pt 3), 344-347 (1995).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/07/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 • USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM